These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17298297)

  • 1. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
    Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
    Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid signaling and liver therapeutics.
    Mallat A; Teixeira-Clerc F; Lotersztajn S
    J Hepatol; 2013 Oct; 59(4):891-6. PubMed ID: 23567085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The endocannabinoid system as a novel target for the treatment of liver fibrosis].
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Hezode C; Mallat A; Lotersztajn S
    Pathol Biol (Paris); 2008 Feb; 56(1):36-8. PubMed ID: 17412522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings.
    Mallat A; Teixeira-Clerc F; Deveaux V; Manin S; Lotersztajn S
    Br J Pharmacol; 2011 Aug; 163(7):1432-40. PubMed ID: 21457226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
    Teixeira-Clerc F; Julien B; Grenard P; Tran Van Nhieu J; Deveaux V; Li L; Serriere-Lanneau V; Ledent C; Mallat A; Lotersztajn S
    Nat Med; 2006 Jun; 12(6):671-6. PubMed ID: 16715087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cannabinoids in chronic liver diseases.
    Parfieniuk A; Flisiak R
    World J Gastroenterol; 2008 Oct; 14(40):6109-14. PubMed ID: 18985799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.
    Giannone FA; Baldassarre M; Domenicali M; Zaccherini G; Trevisani F; Bernardi M; Caraceni P
    Lab Invest; 2012 Mar; 92(3):384-95. PubMed ID: 22184091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.
    Svízenská I; Dubový P; Sulcová A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):501-11. PubMed ID: 18584858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus.
    Zheng L; Wu X; Dong X; Ding X; Song C
    Alcohol Clin Exp Res; 2015 Oct; 39(10):1908-16. PubMed ID: 26343919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of cannabinoid receptors in renal diseases].
    François H; Durrbach A; Beaudreuil S; Charpentier B; Lecru L
    Nephrol Ther; 2016 Apr; 12 Suppl 1():S115-22. PubMed ID: 26968477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids as novel mediators of liver diseases.
    Mallat A; Lotersztajn S
    J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.
    Muñoz-Luque J; Ros J; Fernández-Varo G; Tugues S; Morales-Ruiz M; Alvarez CE; Friedman SL; Arroyo V; Jiménez W
    J Pharmacol Exp Ther; 2008 Feb; 324(2):475-83. PubMed ID: 18029545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CB2 receptors as new therapeutic targets for liver diseases.
    Lotersztajn S; Teixeira-Clerc F; Julien B; Deveaux V; Ichigotani Y; Manin S; Tran-Van-Nhieu J; Karsak M; Zimmer A; Mallat A
    Br J Pharmacol; 2008 Jan; 153(2):286-9. PubMed ID: 17952109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptors in the kidney.
    Hryciw DH; McAinch AJ
    Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):459-64. PubMed ID: 27367912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the endocannabinoid system in drug addiction.
    Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
    Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocannabinoids: therapeutic perspectives in chronic liver diseases].
    Lotersztajn S; Teixeira-Clerc F; Hezode C; Tran van Nhieu J; Deveaux V; Mallat A
    Gastroenterol Clin Biol; 2007 Mar; 31(3):255-8. PubMed ID: 17396081
    [No Abstract]   [Full Text] [Related]  

  • 18. Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
    Julien B; Grenard P; Teixeira-Clerc F; Van Nhieu JT; Li L; Karsak M; Zimmer A; Mallat A; Lotersztajn S
    Gastroenterology; 2005 Mar; 128(3):742-55. PubMed ID: 15765409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans.
    Li C; Bowe JE; Huang GC; Amiel SA; Jones PM; Persaud SJ
    Diabetes Obes Metab; 2011 Oct; 13(10):903-10. PubMed ID: 21564460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin and hemopressin treatment attenuates cholestasis-induced liver fibrosis in rats: role of CB1 receptors.
    El Swefy S; Hasan RA; Ibrahim A; Mahmoud MF
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):103-16. PubMed ID: 26475620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.